CD79A and in situ carcinoma: By comparing the abundance of each Ig-specific subset between CIS/MS patients and controls, the CD27- and Tbet+/CD21low IgA+ were increased two-fold in CIS/MS patients, and a minor increase in the CD27+/CD24hi subset was also observed compared to controls.